CPIX

MKT CAP:$62M

Cumberland Pharmaceuticals Inc.

Market Cap

$62M

Healthcare·Drug Manufacturers - Specialty & Generic·🇺🇸 United States·NASDAQ

Healthcare·Drug·🇺🇸·NASDAQ

Stock Price

$3.05-$0.93 (-23.37%)

Apr 21, 2026

Company Details

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United...

CEO

A. J. Kazimi

IPO Date

Aug 11, 2009

Website

www.cumberlandpharma.com

Key Metrics TTM

Revenue

$43M

+13.0% YoY

Net Income

-$6M

EPS (Diluted)

-$0.41

Free Cash Flow

$3M

Revenue / Share

$2.89

Gross Margin

83.3%

Operating Margin

-13.7%

Net Margin

-13.9%

FCF Margin

6.6%

P/S

1.4x

P/E

—

Earnings Reports

Q1 2026

May 5, 2026

PENDING

FY 2025

Mar 6, 2026

$45M+17.6%EPS -$0.19

Q4 2025

Mar 6, 2026

$14M+31.1%EPS -$0.09

Q3 2025

Nov 7, 2025

$8M-8.7%EPS -$0.13

Q2 2025

Aug 8, 2025

$11MEPS -$0.05

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q2 17	$9M	$7M	-$2M
Q1 22	$11M	$9M	-$1M
Q4 23	$9M	$8M	-$6M
Q3 24	$9M	$8M	-$2M
Q4 24	$10M	$8M	-$2M
Q2 25	$11M	$9M	-$747.5K
Q3 25	$8M	$7M	-$2M
Q4 25	$14M	$11M	-$1M

Valuation

Quarter	P/S	P/E
Q2 17	—	—
Q1 22	—	—
Q4 23	—	—
Q3 24	1.6x	—
Q4 24	1.6x	—
Q2 25	1.6x	—
Q3 25	1.6x	—
Q4 25	1.4x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q2 17	-$3M	-$3M
Q1 22	-$150.5K	-$177.5K
Q4 23	$1M	$953.4K
Q3 24	$475.5K	$516.3K
Q4 24	$2M	$2M
Q2 25	$843.8K	$817.3K
Q3 25	$187.2K	$163.4K
Q4 25	$3.0K	$3.0K

Capital Expenditures

Quarter	CapEx
Q2 17	$319.1K
Q1 22	$27.0K
Q4 23	$86.7K
Q3 24	$40.8K
Q4 24	$26.8K
Q2 25	$26.5K
Q3 25	$23.8K
Q4 25	$6

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 24	+20.4%	+18.6%
Q2 25	-3.0%	-7.1%
Q3 25	-11.3%	-34.0%
Q4 25	+50.5%	+39.6%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q2 17	$296.7K	3.4%
Q1 22	$0	0.0%
Q4 23	$93.9K	1.0%
Q3 24	$76.4K	0.8%
Q4 24	$74.8K	0.7%
Q2 25	$80.7K	0.7%
Q3 25	$0	0.0%
Q4 25	$0	0.0%

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q2 17	$1M	$2M	$5M
Q1 22	$2M	$2M	$5M
Q4 23	$1M	$3M	$5M
Q3 24	$1M	$3M	$4M
Q4 24	$1M	$3M	$4M
Q2 25	$1M	$3M	$4M
Q3 25	$1M	$3M	$4M
Q4 25	$2M	$4M	$6M

Revenue Segments

Quarter	Acetadote	Caldolor	Ethyol	Kristalose	Omeclamox-Pak	Other Products	Vaprisol	Grant	Redi Trex	Sancuso	Vibativ
Q2 17	$2M	$1M	$2M	$3M	$377.5K	$242.8K	$276.7K	—	—	—	—
Q1 22	$111.1K	$959.6K	—	$4M	$22.7K	$295.6K	-$117.0K	$40.0K	$59.2K	$3M	$3M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$17M	$0	$17M
Q2 22	$18M	$0	$18M
Q3 22	$20M	$0	$20M
Q4 22	$20M	$0	$20M
Q1 23	$16M	$0	$16M
Q2 23	$18M	$0	$18M
Q3 23	$19M	$0	$19M
Q4 23	$18M	$0	$18M
Q1 24	$19M	$0	$19M
Q2 24	$17M	$0	$17M
Q3 24	$17M	$0	$17M
Q4 24	$18M	$0	$18M
Q1 25	$15M	$0	$15M
Q2 25	$16M	$0	$16M
Q3 25	$15M	$0	$15M
Q4 25	$11M	$0	$11M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q2 17	16M	—	—
Q1 22	15M	-8.2%	—
Q4 23	14M	-3.6%	—
Q3 24	14M	-0.8%	—
Q4 24	14M	-0.6%	-12.7%
Q2 25	15M	+7.1%	+1.8%
Q3 25	15M	-0.0%	+5.6%
Q4 25	15M	+0.0%	+6.4%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q2 17	$105.7K	82
Q1 22	$134.6K	83
Q4 23	$102.8K	91
Q3 24	$99.8K	91
Q4 24	$114.7K	91
Q2 25	$119.1K	91
Q3 25	$91.1K	91
Q4 25	$147.1K	93

Revenue / Employee